Human mesenchymal stem cell therapy in severe COVID-19 patients: 2-year follow-up results of a randomized, double-blind, placebo-controlled trial-Reference-Cited by-同舟云学术

Human mesenchymal stem cell therapy in severe COVID-19 patients: 2-year follow-up results of a randomized, double-blind, placebo-controlled trial

Published:2023-06 Issue: Volume:92 Page:104600
ISSN:2352-3964
Container-title:eBioMedicine
language:en
Short-container-title:eBioMedicine

Author:

Li Tian-Tian,Zhang Bo,Fang Hui,Shi Ming,Yao Wei-Qi,Li Yuanyuan,Zhang Chao^ORCID,Song Jinwen,Huang Lei,Xu Zhe,Yuan Xin,Fu Jun-Liang,Zhen Cheng,Zhang Yu^ORCID,Wang Ze-Rui,Zhang Zi-Ying,Yuan Meng-Qi,Dong Tengyun,Bai Ruidan,Zhao Lulu,Cai Jianming,Dong Jinghui,Zhang Jianzeng,Xie Wei-Fen,Li Yonggang,Shi Lei^ORCID,Wang Fu-Sheng^ORCID

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Reference25 articles.

1. Two-year health outcomes in hospitalized COVID-19 survivors in China;Yang;JAMA Netw Open,2022

2. Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients;Taquet;Lancet Psychiatr,2022

3. Sustained abnormality with recovery of COVID-19 convalescents: a 2-year follow-up study;Lin;Sci Bull,2022

4. Therapeutic advances in COVID-19;Murakami;Nat Rev Nephrol,2022

5. Transplantation of ACE2(-) mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia;Leng;Aging Dis,2020

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cellular response in the pathogenesis of COVID-19;COVID-19: An Update;2024-09-01

2. Mesenchymal stem cell-based therapy for paraquat-induced lung injury;Cell Biology and Toxicology;2024-08-13

3. Comprehensive Review of COVID-19: Epidemiology, Pathogenesis, Advancement in Diagnostic and Detection Techniques, and Post-Pandemic Treatment Strategies;International Journal of Molecular Sciences;2024-07-26

4. Mesenchymal stem/stromal cells alleviate early‐stage pulmonary fibrosis in a uPAR‐dependent manner;Cell Biology International;2024-07-18

5. Next-generation treatments: Immunotherapy and advanced therapies for COVID-19;Heliyon;2024-03